Open Medicine EU

Archives for Uncategorized

I heard a powerful case recently for access to all clinical trial results. The case was made by Professor Peter C. Gøtzsche, leader of the Nordic Cochrane Collaboration in Copenhagen and one of those whose complaint to the European Ombudsman has led to major improvements in transparency in the European Medicines Agency. The occasion was… » read more

Posted by Jim Murray

Through misuse, non-compliance, and over-prescribing, as well as natural factors, we are running out of useful antibiotics. Four of the articles chosen as national finalists for the European Health Journalist prize 2011 are about the crisis. The titles of three of the articles give a flavour of the issue: “The end of Antibiotics” (Lithuania), “Losing… » read more

Posted by Jim Murray

In my post on the Innovative Medicines Initiative I mentioned the danger that industry subsidies might sometimes be “little more than corporate social welfare, subsidising an already rich industry or, worse, paying for something that industry would otherwise have done for itself”. That was meant as a general point and not as a specific comment… » read more

Posted by Jim Murray

What’s New?

I mentioned in passing in my last post that new medicines are not necessarily innovative. This can be seen in the 2010 Report of the French National Health Authority, the “Haute Autorité de santé”. The authority’s “Commission de la Transparence (évaluation des médicaments)” evaluates the efficacy of each medicine under two headings – the therapeutic… » read more

Posted by Jim Murray

I spent an interesting morning last week in the European Parliament at a presentation of the Innovative Medicines Initiative. IMI is a joint undertaking between the European pharmaceutical association EFPIA and the EU to carry out projects, mostly in pre-competitive research, to help develop new and innovative medicines. (New medicines are not necessarily innovative –… » read more

Posted by Jim Murray

The recent conference in Cork on conflict of interest was extremely interesting and will provide the basis for a few posts on this blog – the speakers’ presentation can be seen here. In a well received intervention, Noel Wathion of the European Medicines Agency announced that the agency would now publish an electronic declaration of… » read more

Posted by Jim Murray

My summer holidays are over and now I’m back to my normal retirement… My friends at Health Action International have asked me to moderate a session at their conference on conflicts of interest in medicine on 24th September in Cork (“Liege” in French?) so, apart from meeting interesting people and hearing interesting things, I have… » read more

Posted by Jim Murray

Holidays!!

I am on holidays during July and much of August, and probably will not be posting during that time, although I will occasionally check for comments, if any. I hope to resume blogging during August. Best wishes, Jim

Posted by Jim Murray

I will deal with the issues of science and patients later but this is a brief summary of some of the legal consequences to date of the J&J bribery case in Greece, Poland and Romania, described in my previous post. In the settlement with the US Department of Justice the company admitted that its subsidiaries,… » read more

Posted by Jim Murray

The US Securities and Exchange Commission reached a settlement with Johnson & Johnson on 11th April over charges of bribing doctors and public hospital adminstrators in Greece, Poland and Romania. The SEC complaint can be read here and includes the following: “Since at least 1998 and continuing to early 2006, J&J’s subsidiaries, employees and agents… » read more

Posted by Jim Murray